The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy

L. Maffioli, L. Florimonte, L. Fugazzola, E. Banti, M. Bagnasco, M. E. Dottorini, G. Perotti, D. Rubello, E. Seregni, E. Bombardieri, O. Testori

Research output: Contribution to journalArticle

Abstract

Recently, in Italy, the reimbursement for the use of rhTSH in preparing patients for radiometabolic treatment of iodine-avid metastases from differentiated thyroid cancer has been made possible. Intramuscular administration of rhTSH increases the radioiodine uptake and thyroglobulin production by thyroid cells. In addition to the previous indications on the use of rhTSH (mainly: serum thyreoglobulin assay with or without 131I scintigraphy and ablation with 131I of remnants in low risk patients), the reimbursement is now allowed for the treatment with radioiodine of iodine-avid loco-regional and distant metastases, in subjects with inability to reach adequate TSH levels and/or severe clinical conditions which could be potentially worsened by other concurrent diseases (history of stroke or transient ischemic attack, severe cardiac disease, renal failure or major psychiatric disorders). The Italian Medicines Agency (AIFA) approved this use (and added this hormone in the special list of drugs regulated by the D.Lgs 648/96) on the basis of a series of scientific evidences, proposed by a "team of experts". In the present paper we illustrate the scientific background of the use of rhTSH (clinical usefulness, economic considerations, aspects related to a better quality of life) that allowed the modification of the reimbursement and how it was made possible in the Italian legislative context.

Original languageEnglish
Pages (from-to)476-484
Number of pages9
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume56
Issue number5
Publication statusPublished - Oct 2012

Fingerprint

Thyrotropin Alfa
Thyroid Neoplasms
Italy
Iodine
Neoplasm Metastasis
Thyroglobulin
Transient Ischemic Attack
Radionuclide Imaging
Renal Insufficiency
Psychiatry
Heart Diseases
Thyroid Gland
Stroke
Economics
Quality of Life
Hormones
Therapeutics
Serum
Pharmaceutical Preparations

Keywords

  • Neoplasm metastases
  • Thyroid neoplasms
  • Thyrotropin alfa

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy. / Maffioli, L.; Florimonte, L.; Fugazzola, L.; Banti, E.; Bagnasco, M.; Dottorini, M. E.; Perotti, G.; Rubello, D.; Seregni, E.; Bombardieri, E.; Testori, O.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 56, No. 5, 10.2012, p. 476-484.

Research output: Contribution to journalArticle

Maffioli, L, Florimonte, L, Fugazzola, L, Banti, E, Bagnasco, M, Dottorini, ME, Perotti, G, Rubello, D, Seregni, E, Bombardieri, E & Testori, O 2012, 'The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy', Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 56, no. 5, pp. 476-484.
Maffioli, L. ; Florimonte, L. ; Fugazzola, L. ; Banti, E. ; Bagnasco, M. ; Dottorini, M. E. ; Perotti, G. ; Rubello, D. ; Seregni, E. ; Bombardieri, E. ; Testori, O. / The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2012 ; Vol. 56, No. 5. pp. 476-484.
@article{81f2bd0ebdf5456799f1dde3c0607fab,
title = "The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy",
abstract = "Recently, in Italy, the reimbursement for the use of rhTSH in preparing patients for radiometabolic treatment of iodine-avid metastases from differentiated thyroid cancer has been made possible. Intramuscular administration of rhTSH increases the radioiodine uptake and thyroglobulin production by thyroid cells. In addition to the previous indications on the use of rhTSH (mainly: serum thyreoglobulin assay with or without 131I scintigraphy and ablation with 131I of remnants in low risk patients), the reimbursement is now allowed for the treatment with radioiodine of iodine-avid loco-regional and distant metastases, in subjects with inability to reach adequate TSH levels and/or severe clinical conditions which could be potentially worsened by other concurrent diseases (history of stroke or transient ischemic attack, severe cardiac disease, renal failure or major psychiatric disorders). The Italian Medicines Agency (AIFA) approved this use (and added this hormone in the special list of drugs regulated by the D.Lgs 648/96) on the basis of a series of scientific evidences, proposed by a {"}team of experts{"}. In the present paper we illustrate the scientific background of the use of rhTSH (clinical usefulness, economic considerations, aspects related to a better quality of life) that allowed the modification of the reimbursement and how it was made possible in the Italian legislative context.",
keywords = "Neoplasm metastases, Thyroid neoplasms, Thyrotropin alfa",
author = "L. Maffioli and L. Florimonte and L. Fugazzola and E. Banti and M. Bagnasco and Dottorini, {M. E.} and G. Perotti and D. Rubello and E. Seregni and E. Bombardieri and O. Testori",
year = "2012",
month = "10",
language = "English",
volume = "56",
pages = "476--484",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy

AU - Maffioli, L.

AU - Florimonte, L.

AU - Fugazzola, L.

AU - Banti, E.

AU - Bagnasco, M.

AU - Dottorini, M. E.

AU - Perotti, G.

AU - Rubello, D.

AU - Seregni, E.

AU - Bombardieri, E.

AU - Testori, O.

PY - 2012/10

Y1 - 2012/10

N2 - Recently, in Italy, the reimbursement for the use of rhTSH in preparing patients for radiometabolic treatment of iodine-avid metastases from differentiated thyroid cancer has been made possible. Intramuscular administration of rhTSH increases the radioiodine uptake and thyroglobulin production by thyroid cells. In addition to the previous indications on the use of rhTSH (mainly: serum thyreoglobulin assay with or without 131I scintigraphy and ablation with 131I of remnants in low risk patients), the reimbursement is now allowed for the treatment with radioiodine of iodine-avid loco-regional and distant metastases, in subjects with inability to reach adequate TSH levels and/or severe clinical conditions which could be potentially worsened by other concurrent diseases (history of stroke or transient ischemic attack, severe cardiac disease, renal failure or major psychiatric disorders). The Italian Medicines Agency (AIFA) approved this use (and added this hormone in the special list of drugs regulated by the D.Lgs 648/96) on the basis of a series of scientific evidences, proposed by a "team of experts". In the present paper we illustrate the scientific background of the use of rhTSH (clinical usefulness, economic considerations, aspects related to a better quality of life) that allowed the modification of the reimbursement and how it was made possible in the Italian legislative context.

AB - Recently, in Italy, the reimbursement for the use of rhTSH in preparing patients for radiometabolic treatment of iodine-avid metastases from differentiated thyroid cancer has been made possible. Intramuscular administration of rhTSH increases the radioiodine uptake and thyroglobulin production by thyroid cells. In addition to the previous indications on the use of rhTSH (mainly: serum thyreoglobulin assay with or without 131I scintigraphy and ablation with 131I of remnants in low risk patients), the reimbursement is now allowed for the treatment with radioiodine of iodine-avid loco-regional and distant metastases, in subjects with inability to reach adequate TSH levels and/or severe clinical conditions which could be potentially worsened by other concurrent diseases (history of stroke or transient ischemic attack, severe cardiac disease, renal failure or major psychiatric disorders). The Italian Medicines Agency (AIFA) approved this use (and added this hormone in the special list of drugs regulated by the D.Lgs 648/96) on the basis of a series of scientific evidences, proposed by a "team of experts". In the present paper we illustrate the scientific background of the use of rhTSH (clinical usefulness, economic considerations, aspects related to a better quality of life) that allowed the modification of the reimbursement and how it was made possible in the Italian legislative context.

KW - Neoplasm metastases

KW - Thyroid neoplasms

KW - Thyrotropin alfa

UR - http://www.scopus.com/inward/record.url?scp=84871821067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871821067&partnerID=8YFLogxK

M3 - Article

C2 - 23069926

AN - SCOPUS:84871821067

VL - 56

SP - 476

EP - 484

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 5

ER -